The pharmaceutical industry is focusing on whether the second-generation BTK inhibitor 'Brukinsa' will overcome the last stage and acquire insurance reimbursement expansion.

According to industry experts, BeiGene Korea is in negotiations with the National Health Insurance Service (NHIS) seeking approval for Brukinsa (zanubrutinib) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL) indications.

If there are no expected delays in the negotiations, Brukinsa is set to be expanded for reimbursement in the first half of the year.

The following indications for Brukinsa are included for expanding reimbursement: monothera